REGN Regeneron Pharmaceuticals, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
REGN Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$733.04
Analyst Target
$826.04
+12.7%
Upside
52W High
$821.11
52W Low
$476.49
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 17, 2026
Market cap
$77.69B
P/E
17.58
ROE
15.2%
Profit margin
32.1%
Debt/Equity
0.09
Dividend yield
0.47%
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a mixed profile: the Piotroski F-Score of 4/9 indicates stable but not strong financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite solid profitability metrics—such as a 32.13% profit margin and 29.56% operating margin—revenue growth is nearly flat at 0.90% YoY, and recent quarterly EPS growth has turned negative. The stock trades below the growth-based intrinsic value of $1,230.15 but above the defensive Graham Number of $531.55, suggesting valuation depends heavily on growth assumptions. Analysts recommend a 'buy' with a $826.04 target, yet insider activity is bearish, and technical trends are weak, offsetting fundamental strengths.
Key Strengths
High profitability with a 32.13% net profit margin, well above sector average of 9.99%
Strong balance sheet indicated by a current ratio of 4.06 and quick ratio of 3.19
Low leverage with a Debt/Equity ratio of 0.09, significantly below sector average of 0.92
Consistently beats earnings estimates, with 3 out of last 4 quarters above expectations and a strong historical surprise average
Attractive analyst target price of $826.04 implying ~12.7% upside from current levels
Key Risks
Weak Piotroski F-Score of 4/9 suggests suboptimal financial stability and operational efficiency trends
Near-zero revenue growth (0.90% YoY) raises concerns about top-line sustainability despite earnings growth
Recent Q/Q and YoY EPS declines (-8.2% and -5.1% respectively) indicate deteriorating earnings momentum
Bearish insider sentiment with $1.20M in net selling and no insider buys in the last 6 months
Technical trend score of 0/100 signals strong short-term bearish momentum, with -8.0% weekly and -2.2% monthly returns
AI Fair Value Estimate
Based on comprehensive analysis
$826.04
+12.7% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
61
Strong
70
55
78
62
40
AI Verdict
Neutral with upside potential if growth reaccelerates
Key drivers: High profitability and low debt support resilience, Analyst optimism and valuation gap vs intrinsic value, Weak Piotroski score and insider selling cap upside
Confidence
75%
Value
70/100
Ref P/E, PEG, Graham Number
Positives
- Current price ($733.04) below analyst target ($826.04)
- P/E of 17.58 is below sector average of 256.48 (excluding outliers)
- Trading above Graham Number ($531.55), suggesting some margin of safety
Watchpoints
- PEG Ratio unavailable; growth not clearly justifying P/E premium
- EV/EBITDA and other key multiples missing, limiting valuation depth
Future
55/100
Ref Growth rates
Positives
- Forward P/E of 16.22 suggests earnings expectations are priced efficiently
- Historical earnings surprise trend indicates potential for positive catalysts
Watchpoints
- Revenue growth of 0.90% YoY is extremely weak for a biotech firm
- Q/Q and YoY EPS growth both negative recently (-8.2%, -5.1%)
- No PEG ratio due to uncertain growth path
Past
78/100
Ref Historical trends
Positives
- Long history of beating earnings estimates (22 of 25 quarters positive surprises)
- Average earnings surprise of +26.13% over last 4 quarters
- Strong historical EPS growth prior to recent downturn
Watchpoints
- Earnings growth has decelerated sharply since 2022
- Most recent quarters show declining EPS despite prior strength
Health
62/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 4/9 indicates stable, not distressed, financial condition
- Very strong liquidity (Current Ratio: 4.06, Quick Ratio: 3.19)
- Exceptionally low Debt/Equity of 0.09 reduces solvency risk
Watchpoints
- Piotroski score below 5 signals weaknesses in profitability, leverage, or operating efficiency trends
- Altman Z-Score missing, limiting distress risk analysis
Dividend
40/100
Ref Yield, Payout
Positives
- Low payout ratio of 6.33% leaves room for future increases
- Dividend has been initiated, signaling maturity and cash return policy
Watchpoints
- Dividend yield of 0.47% is minimal and unattractive for income investors
- Dividend Strength score of 25/100 reflects weak yield and limited history
- No 5-year average yield data, suggesting short dividend track record
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$733.04
Analyst Target
$826.04
Upside/Downside
+12.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for REGN and closest competitors.
Updated 2026-01-16
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
REGN
Regeneron Pharmaceuticals, Inc.
Primary
|
+38.1% | +1.2% | +6.3% | +35.5% | -2.2% | -8.0% |
|
CI
The Cigna Group
Peer
|
+34.8% | -8.7% | -1.1% | -7.0% | -0.6% | -2.4% |
|
ELV
Elevance Health, Inc.
Peer
|
+23.9% | -18.4% | -0.8% | +36.7% | +8.4% | +0.6% |
|
COR
Cencora, Inc.
Peer
|
+271.1% | +143.6% | +50.2% | +25.1% | +13.4% | +0.5% |
|
BDX
Becton, Dickinson and Company
Peer
|
-13.8% | -13.4% | -14.3% | +10.1% | +2.9% | -2.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
17.58
Forward P/E
16.22
PEG Ratio
N/A
P/B Ratio
2.43
P/S Ratio
5.45
EV/Revenue
4.94
EV/EBITDA
16.19
Market Cap
$77.69B
Profitability
Profit margins and return metrics
Profit Margin
32.13%
Operating Margin
29.56%
Gross Margin
45.83%
ROE
15.19%
ROA
6.16%
Growth
Revenue and earnings growth rates
Revenue Growth
+0.9%
Earnings Growth
+18.0%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+8.9%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.09
Low debt
Current Ratio
4.06
Strong
Quick Ratio
3.19
Excellent
Cash/Share
$82.3
Quarterly Earnings History
EPS performance vs analyst estimates
2026-01-30
$N/A
2025-10-28
$11.83
+22.7% surprise
2025-08-01
$12.89
+52.7% surprise
2025-04-29
$7.27
+3.0% surprise
Healthcare Sector Comparison
Comparing REGN against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
P/E Ratio
17.58
This Stock
vs
164.56
Sector Avg
-89.3%
(Discount)
Return on Equity (ROE)
15.19%
This Stock
vs
-52.77%
Sector Avg
-128.8%
(Below Avg)
Profit Margin
32.13%
This Stock
vs
-20.78%
Sector Avg
-254.7%
(Weaker)
Debt to Equity
0.09
This Stock
vs
6.16
Sector Avg
-98.6%
(Less Debt)
Revenue Growth
0.9%
This Stock
vs
137.39%
Sector Avg
-99.3%
(Slower)
Current Ratio
4.06
This Stock
vs
3.36
Sector Avg
+20.9%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
REGN
Regeneron Pharmaceuticals, Inc.
|
NEUTRAL | $77.69B | 17.58 | 15.2% | 32.1% | $733.04 | |
|
CI
The Cigna Group
|
NEUTRAL | $72.71B | 12.04 | 15.5% | 2.3% | $272.21 | |
|
ELV
Elevance Health, Inc.
|
NEUTRAL | $84.41B | 15.26 | 12.6% | 2.8% | $374.87 | |
|
COR
Cencora, Inc.
|
NEUTRAL | $70.85B | 45.47 | 123.8% | 0.5% | $361.94 | |
|
BDX
Becton, Dickinson and Company
|
NEUTRAL | $57.59B | 35.46 | 6.5% | 7.7% | $201.79 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-07 | BASSLER BONNIE L | Director | Sale | 1,500 | $1,200,000 |
| 2026-01-07 | BASSLER BONNIE L | Director | Option Exercise | 1,500 | $561,180 |
| 2026-01-02 | GOLDSTEIN JOSEPH L | Director | Stock Award | 155 | - |
| 2026-01-02 | GUARINI KATHRYN PH.D. | Director | Stock Award | 155 | - |
| 2026-01-02 | BASSLER BONNIE L | Director | Stock Award | 155 | - |
| 2026-01-02 | ZOGHBI HUDA Y | Director | Stock Award | 155 | - |
| 2026-01-02 | SCHENKEIN DAVID P | Director | Stock Award | 155 | - |
| 2026-01-02 | SING GEORGE LOUIS | Director | Stock Award | 155 | - |
| 2026-01-02 | RYAN ARTHUR F | Director | Stock Award | 155 | - |
| 2026-01-02 | POON CHRISTINE A | Director | Stock Award | 155 | - |
| 2026-01-02 | COLES NEAVELLE ANTHONY | Director | Stock Award | 155 | - |
| 2026-01-02 | THOMPSON CRAIG B | Director | Stock Award | 155 | - |
| 2026-01-02 | BROWN MICHAEL S | Director | Stock Award | 155 | - |
| 2025-12-31 | SCHLEIFER LEONARD S | Chief Executive Officer | Stock Award | 28,570 | - |
| 2025-12-31 | YANCOPOULOS GEORGE D | President | Stock Award | 28,570 | - |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
26 analysts
Truist Securities
2026-01-08
Buy
Buy
B of A Securities
2026-01-07
Underperform
Buy
Morgan Stanley
2025-12-12
Equal-Weight
Equal-Weight
Wells Fargo
2025-12-10
Equal-Weight
Equal-Weight
Canaccord Genuity
2025-12-04
Buy
Buy
BMO Capital
2025-12-04
Outperform
Outperform
Morgan Stanley
2025-12-03
Overweight
Equal-Weight
Scotiabank
2025-11-24
Sector Perform
Sector Perform
HSBC
2025-11-24
Buy
Wells Fargo
2025-11-20
Equal-Weight
Equal-Weight
Past News Coverage
Recent headlines mentioning REGN from our newsroom.
Newest → oldest
No matching news yet.